ROCKVILLE, Md., Sept. 19, 2008 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (AMEX:GTF) Chief Executive Officer Martin Rosendale told the Annual Meeting of Shareholders today that the Company is progressing with its sales and marketing campaign for its proprietary AutoloGel(tm) System indicated for use in chronic wounds, as well as plans to further develop its CT-112 peptide, an anti-inflammatory peptide that has shown favorable pre-clinical activity.
